Want to see ADAG full AI Analyst Report?
ADAG Stock Chart & Stats
$3.97
-$0.15(-7.28%)
At close: 4:00 PM EST
$3.97
-$0.15(-7.28%)
Day’s Range― - ―
52-Week Range$1.30 - $4.85
Previous CloseN/A
Volume1.51K
Average Volume (3M)291.18K
Market Cap
$181.49M
Enterprise Value$64.64M
Total Cash (Recent Filing)$74.52M
Total Debt (Recent Filing)$6.26M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Sep 02, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding66,072,590
10 Day Avg. Volume466,553
30 Day Avg. Volume291,180
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.02
Price to Sales (P/S)9.30
P/FCF Ratio-4.55
Enterprise Value/Market Cap0.36
Enterprise Value/Revenue8.40
Enterprise Value/Gross Profit9.09
Enterprise Value/Ebitda-3.09
Forecast
1Y Price Target
$8.00Price Target Upside101.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.49
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery PlatformAdagene's proprietary antibody discovery and engineering platforms provide a durable competitive advantage by enabling discovery of multiple therapeutic candidates. This technology-driven model supports recurring partnership opportunities, scalable R&D output, and long-term pipeline replenishment beyond any single asset.
Promising Clinical Data (muzastotug)Robust Phase 1b/2 signals for muzastotug in difficult solid tumors materially de-risks the program and strengthens its potential as a backbone combo agent. Durable responses and manageable toxicity improve development odds, partnership leverage, and long-term commercial viability if results hold in later trials.
Improved Liquidity PositionA preliminary cash balance of ~$128M materially extends runway for ongoing clinical programs, reducing near-term financing pressure. This liquidity supports execution of trials and business development over the next 2-6 months and lowers the immediate dilution and operational disruption risk.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicates the company is not yet self-funding and remains dependent on external financing. Over time this raises dilution risk, constrains discretionary R&D spend, and makes long-term planning vulnerable to capital markets or partner funding availability.
Volatile Revenue & MarginsWild swings in revenue and a period of negative gross profit signal unstable commercial or collaboration income and inconsistent margin sustainability. This reduces predictability of cash inflows, complicates resource allocation, and weakens confidence in durable revenue growth absent steady partner milestones.
Ongoing Losses & Weak ReturnsDespite improving leverage, persistent operating and net losses produce negative returns on equity and reflect an inability to earn adequate capital returns. If profitability is not achieved, the company faces continued dilution and limited capacity to fund growth from internal resources over the medium term.
Adagene News
ADAG FAQ
What was Adagene, Inc.’s price range in the past 12 months?
Adagene, Inc. lowest stock price was $1.30 and its highest was $4.85 in the past 12 months.
What is Adagene, Inc.’s market cap?
Adagene, Inc.’s market cap is $181.49M.
When is Adagene, Inc.’s upcoming earnings report date?
Adagene, Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 53 days.
How were Adagene, Inc.’s earnings last quarter?
Adagene, Inc. released its earnings results on Apr 01, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.02.
Is Adagene, Inc. overvalued?
According to Wall Street analysts Adagene, Inc.’s price is currently Undervalued.
Does Adagene, Inc. pay dividends?
Adagene, Inc. does not currently pay dividends.
What is Adagene, Inc.’s EPS estimate?
Adagene, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Adagene, Inc. have?
Adagene, Inc. has 66,072,590 shares outstanding.
What happened to Adagene, Inc.’s price movement after its last earnings report?
Adagene, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -13.449%.
Which hedge fund is a major shareholder of Adagene, Inc.?
Currently, no hedge funds are holding shares in ADAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (101.51% Upside)
$8.00 (101.51% Upside)
Blogger Sentiment
Bullish
ADAG Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
104.78%
12-Months-Change
Fundamentals
Return on Equity
-48.20%
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
Adagene, Inc.
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
ADAG Stock 12 Month Forecast
Average Price Target
$8.00
▲(101.51% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
3.72% Other Institutional Investors
96.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---